{"id":"NCT02136069","sponsor":"Hoffmann-La Roche","briefTitle":"A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Na√Øve to Tumor Necrosis Factor (TNF) Inhibitors","officialTitle":"Phase III, Randomized, Multicenter Double-Blind, Double Dummy Study to Evaluate the Efficacy and Safety of Etrolizumab Compared With Infliximab in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12-24","primaryCompletion":"2020-06-23","completion":"2020-06-23","firstPosted":"2014-05-12","resultsPosted":"2021-08-13","lastUpdate":"2021-12-03"},"enrollment":397,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ulcerative Colitis"],"interventions":[{"type":"DRUG","name":"Etrolizumab","otherNames":["PRO145223","RO5490261","RG7413"]},{"type":"DRUG","name":"Infliximab","otherNames":[]},{"type":"OTHER","name":"Placebo (IV)","otherNames":[]},{"type":"OTHER","name":"Placebo (Injection)","otherNames":[]}],"arms":[{"label":"Etrolizumab + Placebo (IV)","type":"EXPERIMENTAL"},{"label":"Infliximab + Placebo (Injection)","type":"ACTIVE_COMPARATOR"}],"summary":"This is a multicenter, Phase III, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety, efficacy, and tolerability of etrolizumab compared with infliximab in treating participants with moderate to severe ulcerative colitis (UC) who are naive to tumor necrosis factor (TNF) inhibitors. Participants will be randomized in a 1:1 ratio to receive either etrolizumab 105 milligrams (mg) by subcutaneous (SC) injection once every 4 weeks (Q4W) + placebo (intravenous \\[IV\\] infusion at Weeks 0, 2, and 6, then once every 8 weeks \\[Q8W\\]) or infliximab 5 milligrams/kilogram (mg/kg) IV at Weeks 0, 2, and 6, then Q8W) + placebo (SC Q4W). Time on treatment is 54 weeks.","primaryOutcome":{"measure":"Percentage of Participants With Both Clinical Response at Week 10 and Clinical Remission at Week 54, as Determined by the Mayo Clinic Score (MCS)","timeFrame":"Week 10, Week 54","effectByArm":[{"arm":"Etrolizumab + Placebo (IV)","deltaMin":18.6,"sd":null},{"arm":"Infliximab + Placebo (Injection)","deltaMin":19.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8114"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":119,"countries":["Austria","Belgium","Canada","Czechia","France","Germany","Hungary","Israel","Italy","Netherlands","Norway","Portugal","Romania","Singapore","South Africa","South Korea","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["34798038","32445184"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":199},"commonTop":["Colitis ulcerative","Nasopharyngitis","Headache","Arthralgia","Abdominal pain"]}}